Western Regional Blog – BC, YK, AB, NWT and Nunavut
A new drug called Niraparib shows promising results to improve the outcome of platinum-sensitive recurrent ovarian cancer. Niraparib is a PARP inhibitor that has been shown in a recent trial to benefit those with and without a BRCA mutation.
It is expected that this drug will be presented to the FDA for approval later this year. The availability of the drug in Canada has not yet been released. There is no information regarding whether or when it will be available.
More details can be found here.